Neurocrine Biosciences (NBIX) Interest & Investment Income (2010 - 2026)
Neurocrine Biosciences (NBIX) posted Interest & Investment Income of $28.1 million for Q1 2026, up 8.91% on a QoQ basis from $25.8 million in Q4 2025, and up 29.49% year-over-year from $21.7 million in Q1 2025.
Neurocrine Biosciences (NBIX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Neurocrine Biosciences' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $28.1 million for Q1 2026.
- Quarterly Interest & Investment Income rose 29.49% year-over-year to $28.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.7 million (up 6.97% YoY) and the FY2025 annual result came in at $90.3 million, down 0.77% from the prior year.
- Interest & Investment Income was $28.1 million for Q1 2026 at Neurocrine Biosciences, up from $25.8 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $28.1 million in Q1 2026 and bottomed at $200000.0 in Q3 2022.
- A 5-year average of $15.7 million and a median of $20.6 million in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income plunged 75.0% — and 2023, when it surged 7150.0%.
- Neurocrine Biosciences' Interest & Investment Income stood at $1.3 million in 2022, then soared by 1353.85% to $18.9 million in 2023, then grew by 19.05% to $22.5 million in 2024, then grew by 14.67% to $25.8 million in 2025, then climbed by 8.91% to $28.1 million in 2026.
- Business Quant data shows NBIX's Interest & Investment Income at $28.1 million in Q1 2026, $25.8 million in Q4 2025, and $22.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.10 Mn |
| Dec 31, 2025 | 25.80 Mn |
| Sep 30, 2025 | 22.20 Mn |
| Jun 30, 2025 | 20.60 Mn |
| Mar 31, 2025 | 21.70 Mn |
| Dec 31, 2024 | 22.50 Mn |
| Sep 30, 2024 | 23.40 Mn |
| Jun 30, 2024 | 22.80 Mn |
| Mar 31, 2024 | 22.30 Mn |
| Dec 31, 2023 | 18.90 Mn |
| Sep 30, 2023 | 14.50 Mn |
| Jun 30, 2023 | 10.70 Mn |
| Mar 31, 2023 | 9.80 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 700,000.00 |
| Sep 30, 2021 | 800,000.00 |
| Jun 30, 2021 | 900,000.00 |